0001209191-19-049105.txt : 20190910
0001209191-19-049105.hdr.sgml : 20190910
20190910210535
ACCESSION NUMBER: 0001209191-19-049105
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190909
FILED AS OF DATE: 20190910
DATE AS OF CHANGE: 20190910
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Aurentz Vincent
CENTRAL INDEX KEY: 0001657494
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-31161
FILM NUMBER: 191087029
BUSINESS ADDRESS:
STREET 1: C/O ARENA PHARMACEUTICALS, INC.
STREET 2: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: (858) 453-7200
MAIL ADDRESS:
STREET 1: C/O ARENA PHARMACEUTICALS, INC.
STREET 2: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER NAME:
FORMER CONFORMED NAME: Vincent Aurentz
DATE OF NAME CHANGE: 20151103
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARENA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001080709
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 232908305
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-453-7200
MAIL ADDRESS:
STREET 1: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-09-09
0
0001080709
ARENA PHARMACEUTICALS INC
ARNA
0001657494
Aurentz Vincent
C/O ARENA PHARMACEUTICALS, INC.
6154 NANCY RIDGE DRIVE
SAN DIEGO
CA
92121
0
1
0
0
Executive VP and CBO
Common Stock
2019-09-09
4
M
0
25000
17.10
A
25000
D
Common Stock
2019-09-09
4
M
0
10000
14.60
A
35000
D
Common Stock
2019-09-09
4
M
0
30000
35.60
A
65000
D
Common Stock
2019-09-09
4
S
0
44672
50.4835
D
20328
D
Common Stock
2019-09-09
4
S
0
20328
51.2348
D
0
D
Employee Stock Option (right to buy)
17.10
2019-09-09
4
M
0
25000
0.00
D
2023-08-15
Common Stock
25000
55000
D
Employee Stock Option (right to buy)
14.60
2019-09-09
4
M
0
10000
0.00
D
2024-02-13
Common Stock
10000
89500
D
Employee Stock Option (right to buy)
35.60
2019-09-09
4
M
0
30000
0.00
D
2025-01-19
Common Stock
30000
100000
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.05 to $50.99, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes 2 and 3 to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.54, inclusive.
The options vest over four years and are exercisable once vested. 25% vested and became exercisable on August 15, 2017. The remainder of the options vest in thirty-six equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share), with the first installment vesting on September 15, 2017, and the thirty-sixth installment vesting on August 15, 2020.
The options vest over four years and are exercisable once vested. 25% vested and became exercisable on February 13, 2018. The remainder of the options vest in thirty-six equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share), with the first installment vesting on March 13, 2018, and the thirty-sixth installment vesting on February 13, 2021.
The options vest over four years and are exercisable once vested. 25% vested and became exercisable on January 19, 2019. The remainder of the options vest in thirty-six equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share), with the first installment vesting on February 19, 2019, and the thirty-sixth installment vesting on January 19, 2022.
/s/ Andrew J. Cronauer, as Attorney-in-Fact
2019-09-10